118252-46-3

Upstream product

• 64-18-6 formic acid 
• 118252-44-1 N-<4-<<3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propyl>amino>benzoyl>-L-glutamic acid 
• 118252-50-9 3-<2-(acetylamino)-4-(diacetylamino)-1,6-dihydro-6-oxo-5-pyrimidinyl>propionaldehyde diethyl acetal 
• 118252-51-0 2-acetamido-8-acetyl-5,6,7,8-tetrahydro-7-hydroxypyrido<2,3-d>pyrimidin-4(3H)-one 
• 52407-60-0 dimethyl N-(4-amino-benzoyl)-L-glutamate 
• 118252-49-6 3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propionaldehyde diethyl acetal 

Relevant academic research and scientific papers

Substituted glutamic acids

The present invention provides a compound of formula (I): STR1 wherein R1 is hydrogen, C1-4 alkyl, acetyl or formyl; R2 and R3 are the same or different and are hydrogen or C1-4 alkyl; R4 i

Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propyl]amino]-b benzoyl]-L-glutamic acid

The synthesis and biological evaluation of N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl) propyl]amino]-benzoyl]-L-glutamic acid (1) (5-DACTHF, 543U76), an acyclic analogue of 5,6,7,8-tetrahydrofolic acid (TFHA), are described. The key intermediat

Pyrimidine compounds

The present invention provides a compound of formula (I): STR1 wherein R1 is hydrogen , C1-4 alkyl, acetyl or formyl; R2 and R3 are the same or different and are hydrogen or C1-4 alkyl; R4